Use of taurolidine, taurultam or a mixture thereof in the preparation of a medicament for the reduction of postoperative complications of cardiopulmonary bypass surgery, said reduction consisting of postoperative complications in one or more of the following: (i ) reduction of reperfusion induced arrhythmias in patients undergoing blood cardioplegia and crystalloid cardioplegia, (ii) improvement of the systemic inflammatory response resulting from ischemic reperfusion damage by attenuating the cascade of proinflammatory mediators in the perioperative period through the negative regulation of proinflammatory interleukin-6 together with the elevation or prevention of the reduction of anti-inflammatory interleukin-10 levels, and (iii) reduction of respiratory compromise after said surgery.
展开▼
